NA-ACCORD COVID-19 Supplment

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U01AI069918-14S1

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population

    Individuals with multimorbidity

  • Occupations of Interest



The North American - AIDS Cohort Collaboration on Research and Design (NA-ACCORD), the Region 1representative of the IeDEA network, aims to describe the HIV epidemic in the US and Canada and answerquestions important to the contemporary care and health of persons with HIV. We propose to leverage theresearch infrastructure of the NA-ACCORD to support our infectious disease epidemiologists and clinical co-investigators as they pivot to answer urgent COVID-19 questions in people with (PWH) and without (PWOH)HIV among existing and new cohorts. By supporting a) 2 existing cohorts and the establishment of 3longitudinal COVID-19 clinical cohorts curated from available electronic health record (EHR data), b) datamanagement and analytic expertise specific to the profound health impacts of infectious disease, c) a library ofCOVID-19 data collection tools, and d) the sharing of EHR-based algorithms for COVID-19, we will acceleratethe answers to the following urgent COVID-19 questions: 1) Who is getting tested for SARS-Cov-2, whatproportion are positive, and what are predictors of a positive test? 2) What are risk factors for hospitalizationafter testing positive for SARS-Cov-2? 3) Do angiotensin-converting enzymes (ACE) inhibitors or angiotensin IItype-I receptor blockers (ARBs) increase the risk of severe COVID-19 illness? 4) What is the impact of thehealthcare system's adaptation to the surge of people becoming ill with COVID-19 on the all-cause mortalityamong those with HIV (a chronic condition that requires routine care)? Infectious disease epidemiologists andclinicians are needed to answer urgent COVID-19 questions. The NA-ACCORD will support co-investigatorsand their analytic teams, provide the infrastructure to share information, and examine the heterogeneity inanswering these COVID-19 questions investigated expeditiously in 5 existing and new cohorts.